Genya Aharon-Hananel1,2, Ruth Percik1,2,3,4, Muhamad Badarna1,2, Inbal Uri1,3,4, Amit Tirosh5,6,7. 1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Division of Endocrinology, Diabetes and Metabolism, The Chaim Sheba Medical Center, Tel Hashomer, Israel. 3. Neuroendocrine Tumors Service, Division of Endocrinology, Diabetes and Metabolism, The Chaim Sheba Medical Center, Tel Hashomer, Israel. 4. Endocrine Oncology Clinic, Cancer Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel. 5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. amit.tirosh@sheba.health.gov.il. 6. Division of Endocrinology, Diabetes and Metabolism, The Chaim Sheba Medical Center, Tel Hashomer, Israel. amit.tirosh@sheba.health.gov.il. 7. Neuroendocrine Tumors Service, Division of Endocrinology, Diabetes and Metabolism, The Chaim Sheba Medical Center, Tel Hashomer, Israel. amit.tirosh@sheba.health.gov.il.
Abstract
OBJECTIVE: To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA). METHODS: Retrospective analysis of the Surveillance Epidemiology and End-Results database (SEER), including patients diagnosed with PC or APA between 1973 and 2015. Age-adjusted Kaplan-Meier analyses were performed, comparing all-cause mortality (ACM) rates before the year 2006, the time of TMZ introduction ("period 1"), and afterwards ("period 2"), in patients harboring PC and APA. RESULTS: Among 107 patients, 18 (16.8%) harbored PC. The prevalence of PC and APA was comparable between genders, ethnicities and age strata. Patients harboring any pituitary tumor (PC or APA) had comparable risk for ACM and disease-specific mortality between the two time periods. However, among patients harboring PC, the risk for ACM was significantly lower in period 2 vs. period 1 (p = 0.021), becoming comparable to the risk of ACM in patients diagnosed with APA (p = 0.48). CONCLUSIONS: In this large cancer-database-based analysis we observed improved overall survival in patients harboring PC in the years following the introduction of TMZ.
OBJECTIVE: To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA). METHODS: Retrospective analysis of the Surveillance Epidemiology and End-Results database (SEER), including patients diagnosed with PC or APA between 1973 and 2015. Age-adjusted Kaplan-Meier analyses were performed, comparing all-cause mortality (ACM) rates before the year 2006, the time of TMZ introduction ("period 1"), and afterwards ("period 2"), in patients harboring PC and APA. RESULTS: Among 107 patients, 18 (16.8%) harbored PC. The prevalence of PC and APA was comparable between genders, ethnicities and age strata. Patients harboring any pituitary tumor (PC or APA) had comparable risk for ACM and disease-specific mortality between the two time periods. However, among patients harboring PC, the risk for ACM was significantly lower in period 2 vs. period 1 (p = 0.021), becoming comparable to the risk of ACM in patients diagnosed with APA (p = 0.48). CONCLUSIONS: In this large cancer-database-based analysis we observed improved overall survival in patients harboring PC in the years following the introduction of TMZ.
Authors: Daniel Bengtsson; Henrik Daa Schrøder; Marianne Andersen; Dominique Maiter; Katarina Berinder; Ulla Feldt Rasmussen; Åse Krogh Rasmussen; Gudmundur Johannsson; Charlotte Hoybye; Aart Jan van der Lely; Maria Petersson; Oskar Ragnarsson; Pia Burman Journal: J Clin Endocrinol Metab Date: 2015-02-03 Impact factor: 5.958
Authors: Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn Journal: Eur J Endocrinol Date: 2007-02 Impact factor: 6.664
Authors: E Guastamacchia; V Triggiani; E Tafaro; A De Tommasi; C De Tommasi; S Luzzi; C Sabbà; F Resta; M R Terreni; M Losa Journal: Minerva Endocrinol Date: 2007-09 Impact factor: 2.184
Authors: Whoon Jong Kil; David Cerna; William E Burgan; Katie Beam; Donna Carter; Patricia S Steeg; Philip J Tofilon; Kevin Camphausen Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531